Back to today’s briefing

Story perspectives

Novo Nordisk Slashes Wegovy Prices Amid Obesity Crisis

12/30/2025

32 8

Summary

Story summary

Novo Nordisk A/S lowered Wegovy prices in China ahead of the 2026 patent expiry, with cuts up to 48% in some provinces.
The move aims to ease treatment costs as 65% of China's population could be overweight or obese by 2030.
Local competitors are preparing to launch their own versions of Wegovy.
Novo Nordisk also reduced prices in India and agreed with Eli Lilly to lower U.S. prices.

1 of 1

Story summary

Novo Nordisk A/S lowered Wegovy prices in China ahead of the 2026 patent expiry, with cuts up to 48% in some provinces.
The move aims to ease treatment costs as 65% of China's population could be overweight or obese by 2030.
Local competitors are preparing to launch their own versions of Wegovy.
Novo Nordisk also reduced prices in India and agreed with Eli Lilly to lower U.S. prices.